文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study.

作者信息

Lim Luigi, Machingura Abigirl, Taye Mekdes, Pe Madeline, Coens Corneel, Martinelli Francesca, Alanya Ahu, Antunes Stéphanie, Tu Dongsheng, Basch Ethan, Ringash Jolie, Brandberg Yvonne, Groenvold Mogens, Eggermont Alexander, Cardoso Fatima, Van Meerbeeck Jan, Koller Michael, Van der Graaf Winette T A, Taphoorn Martin J B, Koekkoek Johan A F, Reijneveld Jaap C, Soffietti Riccardo, Velikova Galina, Bottomley Andrew, Flechtner Henning, Musoro Jammbe

机构信息

European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.

Formerly European Organisation for Research and Treatment of Cancer (EORTC) HQ, Brussels, Belgium.

出版信息

EClinicalMedicine. 2025 Mar 21;82:103153. doi: 10.1016/j.eclinm.2025.103153. eCollection 2025 Apr.


DOI:10.1016/j.eclinm.2025.103153
PMID:40201799
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11976232/
Abstract

BACKGROUND: A pooled data analysis by Quinten et al. (2009) found three European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) health-related quality of life (HRQoL) scales to be prognostic for survival: physical functioning, pain and appetite loss. This study aims to replicate these findings in an independent data set comprising a broader cancer population. METHODS: Data were obtained from 46 clinical trials across three cancer research networks conducted between 1996 and 2013 that assessed HRQoL using the EORTC QLQ-C30. A stratified Cox proportional hazards model was employed to assess the prognostic significance of baseline QLQ-C30 scale scores on overall survival, adjusting for socio-demographic and clinical variables. Stepwise model selection was done at 5% significance level. Model stability and prognostic accuracy were evaluated via bootstrapping and the index respectively. FINDINGS: Data from 16,210 patients reporting HRQoL at baseline, spanning 17 cancer types, was used. The stratified multivariable model confirmed that better physical functioning (hazard ratio [HR], 0.94; 95% confidence interval [CI], 0.93-0.96), lower pain (HR, 1.02; 95% CI, 1.01-1.03), and appetite loss (HR, 1.04; 95% CI, 1.03-1.05) were significantly associated with survival. Additionally, global health status/QoL, dyspnoea, emotional and cognitive functioning were found to be prognostic for survival. This final model, encompassing sociodemographic, clinical, and HRQoL variables, achieved a corrected index of 0.74, marking a 48% enhancement in discriminatory ability. Bootstrap evaluation indicated no major instability issues. INTERPRETATION: These results support previous findings that baseline physical functioning, pain, and appetite loss scores, along with four other scales from the EORTC QLQ-C30, predict survival in cancer patients. FUNDING: EORTC Quality of Life Group.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e590/11976232/c046857003f8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e590/11976232/c046857003f8/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e590/11976232/c046857003f8/gr1.jpg

相似文献

[1]
Prognostic value of baseline EORTC QLQ-C30 scores for overall survival across 46 clinical trials covering 17 cancer types: a validation study.

EClinicalMedicine. 2025-3-21

[2]
The EORTC QLQ-C30 Summary Score as Prognostic Factor for Survival of Patients with Cancer in the "Real-World": Results from the Population-Based PROFILES Registry.

Oncologist. 2020-4

[3]
Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials.

Lancet Oncol. 2009-9

[4]
Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.

Lancet Oncol. 2021-5

[5]
Quality of life as a prognostic indicator of survival: A pooled analysis of individual patient data from canadian cancer trials group clinical trials.

Cancer. 2018-6-15

[6]
Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.

BMC Cancer. 2017-1-4

[7]
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study.

Eur J Cancer. 2022-7

[8]
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial.

Lancet Oncol. 2024-9

[9]
Baseline functioning scales of EORTC QLQ-C30 predict overall survival in patients with gastrointestinal cancer: a meta-analysis.

Qual Life Res. 2024-6

[10]
Baseline functioning scales of quality of life (EORTC QLQ-C30) as a predictor of overall survival in patients with lung cancer: a meta-analysis.

Support Care Cancer. 2025-4-9

本文引用的文献

[1]
Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab.

Bladder Cancer. 2022-3-11

[2]
Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysis.

J Natl Cancer Inst. 2023-12-6

[3]
Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.

Eur J Cancer. 2023-7

[4]
Association Between Quality of Life Questionnaire at Diagnosis and Survival in Patients With Lung Cancer.

Clin Lung Cancer. 2023-7

[5]
Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection.

Nat Commun. 2022-10-12

[6]
Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study.

Eur J Cancer. 2022-7

[7]
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer.

ESMO Open. 2022-6

[8]
The predictive utility of patient-reported outcomes and performance status for survival in metastatic lung cancer patients treated with chemoimmunotherapy.

Transl Lung Cancer Res. 2022-3

[9]
Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.

Oncologist. 2021-7

[10]
Past and Current Practice of Patient-Reported Outcome Measurement in Randomized Cancer Clinical Trials: A Systematic Review.

Value Health. 2021-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索